Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Operating Leases for 7 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 661.2% to $7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, up 661.2% year-over-year, with the annual reading at $7.7 million for FY2025, 661.2% up from the prior year.
  • Operating Leases for Q4 2025 was $7.7 million at Madrigal Pharmaceuticals, up from $5.6 million in the prior quarter.
  • The five-year high for Operating Leases was $7.7 million in Q4 2025, with the low at $71000.0 in Q3 2022.
  • Average Operating Leases over 5 years is $1.6 million, with a median of $900000.0 recorded in 2024.
  • The sharpest move saw Operating Leases plummeted 85.54% in 2022, then skyrocketed 1763.38% in 2023.
  • Over 5 years, Operating Leases stood at $387000.0 in 2021, then crashed by 81.65% to $71000.0 in 2022, then skyrocketed by 1570.42% to $1.2 million in 2023, then fell by 14.17% to $1.0 million in 2024, then soared by 661.2% to $7.7 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $7.7 million, $5.6 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.